| Prev Close | 1.32 |
| Open | 1.30 |
| Day Low/High | 1.23 / 1.31 |
| 52 Wk Low/High | 0.64 / 5.37 |
| Volume | 942.66K |
| Avg Volume | 3.70M |
| Exchange | NASDAQ |
| Shares Outstanding | 101.01M |
| Market Cap | 127.27M |
| EPS | 1.40 |
| P/E Ratio | 0.85 |
| Div & Yield | N.A. (N.A) |
Latest News
MannKind Provides Update On Senior Management
Michael Castagna appointed Chief Executive Officer and Member of MannKind Board of Directors
MannKind Corporation Reports 2017 First Quarter Financial Results
Conference Call to Begin Today at 5:00 PM ET
Mannkind in Free Fall After Changes to Insulin Product, Sales Force
Shares of insulin maker Mannkind plummeted on news of a proposed stock split, staffing changes and a new iteration of its insulin.
Mannkind Stock Drops Following Changes to Its Insulin Product
Mannkind stock is suffering, and the company appears to be in trouble.
Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open
Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.
Insulin Drug Offers Hope for MannKind
The stock has taken a beating, but users of Afrezza are loyal to the drug.
2016 Was a Terrible Year for Biotech but the Tweets Were on Point
2016 tweets by TheStreet's Adam Feuerstein kept us informed and entertained. From an unexpected twist on New Year's day with MannKind to J.P. Morgan's Healthcare conference to Bristol-Myers Squibb's oops!
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
TheStreet's biotech columnist offers his own report card on biotech stocks.
2016 Was a Terrible Year for Biotech but the Tweets Were on Point
A look back at the year's worth of Adam Feuerstein's biotech tweets.
These 5 Stocks Under $10 Could Make You a Lot of Money
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
